Economy/Home · Economy

Samsung Bioepis Signs Biosimilar Commercialization Deal with Teva Worth Up to 563.2 Billion Won... FDA-Approved SB2 and SB4 to Be Sold in the U.S.

Samsung Epis Holdings' subsidiary Samsung Bioepis announced on the 3rd that it has signed a biosimilar commercialization partnership agreement with global pharmaceutical company Teva Pharmaceuticals International GmbH worth up to 420 million dollars (approximately 563.2 billion won). The agreement w

Oseong Kwon
Staff Reporter
5 min read
Samsung Bioepis Signs Biosimilar Commercialization Deal with Teva Worth Up to 563.2 Billion Won... FDA-Approved SB2 and SB4 to Be Sold in the U.S.
CBC News

Samsung Epis Holdings' subsidiary Samsung Bioepis announced on the 3rd that it has signed a biosimilar commercialization partnership agreement with global pharmaceutical company Teva Pharmaceuticals International GmbH worth up to 420 million dollars (approximately 563.2 billion won). The agreement was signed on the 2nd, U.S. Eastern Time.

The contract amount is equivalent to about 34% of Samsung Bioepis' consolidated revenue of 1,671,965,484,020 won for 2025.

FDA-Approved SB2 and SB4 Targeted... Teva to Handle U.S. Sales

The products covered by the agreement are SB2 (a Remicade biosimilar), a treatment for Crohn's disease, ulcerative colitis, and rheumatoid arthritis, and SB4 (an Enbrel biosimilar), a treatment for rheumatoid arthritis, psoriatic arthritis, and psoriasis. Both products have received approval from the U.S. Food and Drug Administration (FDA).

Under the agreement, Samsung Bioepis will be responsible for the development, manufacturing, and supply of the products, while Teva will handle sales in the U.S. market. The two companies agreed to share profits from product commercialization as stipulated in the contract.

Contract Consists of Upfront Payment and Milestones... $50 Million Upfront to Be Received Within 30 Days

The contract amount consists of: an upfront payment of up to 75 million dollars (approximately 100.6 billion won) with no obligation to repay; launch milestones of up to 75 million dollars (approximately 100.6 billion won); and sales milestones of up to 270 million dollars (approximately 362.1 billion won).

Of the upfront payment, 50 million dollars is to be received within 30 days of the contract's effective date, while the remaining 25 million dollars will be paid upon satisfaction of conditions specified in the agreement. Launch and sales milestones will also be received in stages depending on the achievement of conditions such as product launches and reaching certain cumulative sales figures.

Conditional Contract... Actual Amount and Timing of Payments May Vary

However, as this is a conditional contract, the actual amounts received and their timing may vary depending on product launches and sales performance. If specific events occur, such as review results from relevant regulatory authorities or failure to meet contract conditions, the agreement may be terminated in whole or in part, or its terms may be changed.

The contract period was not disclosed for reasons of business confidentiality, and the disclosure exemption deadline is April 1, 2039. Samsung Bioepis stated that it will promptly disclose any changes to the key terms or any disclosure obligations that may arise.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.